Individualization of levodopa infusion through objective symptom quantification
|Coordinator||Akademiska Sjukhuset - Neurologiska kliniken|
|Funding from Vinnova||SEK 500 000|
|Project duration||May 2019 - April 2020|
|Call||Medtech4Health: Support for Innovators in Care and Healthcare 2019|
Purpose and goal
The project will experimentally evaluate the functionality and feasibility of objective symptom quantification for dose titration of Duodopa® pump (originally developed in Sweden) within Parkinson’s disease, as a replacement or complement of today’s subjective assessments. Objective quantification of motor symptoms and oculodynamics constitute part of the cloud-based platform sPark that is currently under development at the department of Information Technology, Uppsala University, in cooperation with Neurology at Uppsala University Hospital and Stardots AB.
Expected results and effects
Quantification of motor symptoms and oculodynamics will be performed in five patients at the neurology ward of Uppsala University Hospital in parallel with and independent of the standard titration procedure for Duodopa®. The symptom quantification results will be translated to the Treatment Response Scale to facilitate the comparison with the outcome of subjective evaluation by medical personnel.
Planned approach and implementation
Five consecutive patients undergoing Duodopa® pump titration will be included. Initial dosing will be calculated, based on previous oral treatment. Patient mobility is evaluated once an hour during daytime, which is the usual procedure for dose titration. A smartphone is used for tremor measurement. Oculodynamics are evaluated in a smooth pursuit test with the visual stimuli presented on the screen of a tablet computer and the response is registered by an attached eye tracker.